Shane Bohnen, Senior Vice President and General Counsel of BIO-TECHNE Corp, filed an amended statement of changes in beneficial ownership on November 2, 2026, reporting multiple equity transactions dated August 15, 2026.

Key Highlights

  • Reporting person: Shane Bohnen, SVP and General Counsel of BIO-TECHNE Corp (NASDAQ:TECH)
  • Discretionary vesting authorized: The Board of Directors authorized discretionary vesting of 995 performance stock options and 370 performance restricted stock units on August 15, 2026; the remaining performance options and performance RSUs were forfeited, according to the filing.
  • Tax withholding disposition: 1,366 shares of common stock were disposed of at $72.4 per share on August 15, 2026, under transaction code F.
  • Post-transaction direct holdings: Bohnen directly held 10,407 shares of common stock following the reported transactions.
  • RSU vesting schedule: 2,332 restricted stock units vest on each of August 15, 2026, August 15, 2027, and August 15, 2028, leaving 4,664 units remaining; 1,669 units vest on each of August 15, 2026 and August 15, 2027, leaving 1,669 units remaining.
  • Amendment details: This filing amends an original statement filed on August 18, 2026, with the earliest transaction date of August 15, 2026.

Equity Award Activity for Bio-Techne's General Counsel in August 2026

According to the filing, BIO-TECHNE Corp is identified on NASDAQ under the ticker TECH. The company's equity award structure for its senior officers, as reflected in this disclosure, includes performance stock options, performance restricted stock units, and time-based restricted stock units, each representing a contingent right to receive one share of Bio-Techne common stock upon vesting.

The filing reports that on August 15, 2026, Bohnen received 4,420 shares of common stock through an "M" coded transaction (exercise or conversion of derivative securities), bringing his total direct holdings to 11,773 shares before the withholding transaction. A subsequent "F" coded disposition of 1,366 shares at $72.4 per share reduced his direct common stock holdings to 10,407 shares. The filing attributes the Board of Directors with authorizing discretionary vesting for 995 performance options, while noting that the remainder of the performance options were forfeited. Similarly, 370 performance RSUs were granted discretionary vesting by the Board, with the remaining performance RSUs also forfeited.

On the derivative securities side, Bohnen held 995 performance stock options with an exercise price of $84.61 following the reported transactions. Separately, a tranche of 49 restricted stock units vested fully on August 15, 2026, leaving no remaining balance in that award. The filing was signed by Andrew Nick as Attorney-in-Fact for Shane Bohnen pursuant to a previously filed power of attorney.

What Was Disclosed

This amended filing covers equity transactions for Bio-Techne's SVP and General Counsel Shane Bohnen on August 15, 2026, including Board-authorized discretionary vesting of performance awards, scheduled RSU vesting events, a tax-withholding share disposition, and resulting beneficial ownership balances.